Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 113
Filtrar
1.
Clin Pharmacol Ther ; 101(6): 782-790, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28074556

RESUMO

The effects of isavuconazole (active moiety of isavuconazonium sulfate) on cardiac ion channels in vitro and cardiac repolarization clinically were assessed in a phase I, randomized, double-blind study in healthy individuals who received isavuconazole (after 2-day loading dose), at therapeutic or supratherapeutic doses daily for 11 days, moxifloxacin (400 mg q.d.), or placebo. A post-hoc analysis of the phase III SECURE trial assessed effects on cardiac safety. L-type Ca2+ channels were most sensitive to inhibition by isavuconazole. The 50% inhibitory concentrations for ion channels were higher than maximum serum concentrations of nonprotein-bound isavuconazole in vivo. In the phase I study (n = 161), isavuconazole shortened the QT interval in a dose- and plasma concentration-related manner. There were no serious treatment-emergent adverse events; palpitations and tachycardia were observed in placebo and supratherapeutic isavuconazole groups; no cardiac safety signals were detected in the SECURE study (n = 257). Isavuconazole was associated with a shortened cardiac QT interval.


Assuntos
Potenciais de Ação/efeitos dos fármacos , Antifúngicos/efeitos adversos , Arritmias Cardíacas/induzido quimicamente , Sistema de Condução Cardíaco/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Nitrilas/efeitos adversos , Piridinas/efeitos adversos , Triazóis/efeitos adversos , Adulto , Antifúngicos/farmacocinética , Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/fisiopatologia , Bloqueadores dos Canais de Cálcio/efeitos adversos , Bloqueadores dos Canais de Cálcio/farmacocinética , Canais de Cálcio Tipo L/efeitos dos fármacos , Canais de Cálcio Tipo L/metabolismo , Linhagem Celular , Relação Dose-Resposta a Droga , Método Duplo-Cego , Eletrocardiografia , Feminino , Sistema de Condução Cardíaco/metabolismo , Sistema de Condução Cardíaco/fisiopatologia , Humanos , Masculino , Modelos Biológicos , Nitrilas/farmacocinética , Piridinas/farmacocinética , Medição de Risco , Fatores de Tempo , Transfecção , Triazóis/farmacocinética , Adulto Jovem
2.
Diabetologia ; 48(10): 1980-7, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16082528

RESUMO

AIMS/HYPOTHESIS: We explored the impact of baseline left ventricular hypertrophy (LVH) and losartan treatment on renal and cardiovascular (CV) events in 1,513 patients from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which studied the effects of losartan on the progression of renal disease and/or death in patients with type 2 diabetes and nephropathy. MATERIALS AND METHODS: LVH was assessed using ECG criteria (Cornell product and/or Sokolow-Lyon voltage). The risk of renal or CV events was determined by a proportional hazards model fit with treatment allocation and presence of LVH. Covariates at baseline included age, sex, systolic BP, mean arterial pressure, pulse, proteinuria, serum creatinine, albumin and haemoglobin. RESULTS: A total of 187 subjects (12%) had LVH at baseline. Treatment with losartan resulted in a significant decrease in the Cornell product (-6.2%) and Sokolow-Lyon voltage (-6.3%). LVH was shown to be significantly associated with the primary endpoint, which was a composite of doubling of serum creatinine (DSCR), endstage renal disease (ESRD) or death (hazard ratio [HR]=1.44, p=0.011), as well as with the composite renal endpoint of DSCR/ESRD (HR=1.42, p=0.031) and CV events (HR=1.68, p=0.001). Losartan treatment of patients with LVH decreased the CV as well as renal risk to a level similar to that of patients without LVH. CONCLUSIONS/INTERPRETATION: In patients with type 2 diabetes and nephropathy, LVH is associated with significantly increased risk of CV events and the progression of kidney disease. Importantly, in patients with LVH, losartan reduced the CV as well as the renal risk to a level similar to that seen in subjects without LVH.


Assuntos
Anti-Hipertensivos/uso terapêutico , Complicações do Diabetes/prevenção & controle , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipertrofia Ventricular Esquerda/prevenção & controle , Losartan/uso terapêutico , Idoso , Angiotensina II/antagonistas & inibidores , Doenças Cardiovasculares/prevenção & controle , Nefropatias Diabéticas/prevenção & controle , Método Duplo-Cego , Eletrocardiografia , Determinação de Ponto Final , Feminino , Humanos , Hipertrofia Ventricular Esquerda/etiologia , Hipertrofia Ventricular Esquerda/fisiopatologia , Masculino , Pessoa de Meia-Idade , Medição de Risco , Resultado do Tratamento
3.
Clin Cardiol ; 24(11 Suppl): V9-11, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11712776

RESUMO

The INternational VErapamil SR/trandolapril STudy (INVEST) will provide a large database of information. Proposed substudies for analysis include ambulatory blood pressure monitoring (ABPM), depression, genotyping, atrial fibrillation, electrocardiogram (ECG), echocardiography, renal dysfunction, diabetes, and cardiac care cost estimate. This paper reviews the design and status of several of the INVEST substudies. The ABPM substudy will obtain objective blood pressure recordings during daily life masked to both the patient and the investigator. Ambulatory blood pressure monitoring is an especially useful technology because of the role of nocturnal hypertension and circadian blood pressure irregularities in the development of hypertensive disease. The depression substudy, which enrolled 2,393 patients in the United States, will report quality-of-life (QOL) data, including information regarding energy and fatigue. The genotyping substudy will provide genomic DNA samples from approximately 15,000 patients in the United States, including Puerto Rico. Many candidate genes will be examined for polymorphisms that may predict outcomes and/or responses to various treatments.


Assuntos
Monitorização Ambulatorial da Pressão Arterial , Hipertensão , Depressão/complicações , Genótipo , Humanos , Hipertensão/complicações , Hipertensão/genética , Hipertensão/psicologia
4.
Am J Physiol Heart Circ Physiol ; 281(5): H1968-75, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11668057

RESUMO

The effects of left ventricular hypertrophy (LVH) on the generation of phase 2 early afterdepolarization (EAD) and transmural dispersion of repolarization (TDR) were assessed using arterially perfused rabbit ventricular wedge preparations. Transmembrane action potentials from epicardium, subendocardium, and endocardium were simultaneously recorded together with a transmural ECG. Transmural action potential duration (APD) was also mapped. LVH (renovascular hypertension model) produced significant prolongation in ventricular APD and QT interval. Preferential APD prolongation in subendocardium and endocardium was associated with a marked increase in TDR. Phase 2 EADs were generated from subendocardium or endocardium in all LVH rabbits (15 of 15) in the absence of APD prolonging agents at basic cycle lengths of 2,000-4,000 ms. Phase 2 EAD could produce "R on T" extrasystoles, initiating polymorphic ventricular tachycardia (VT). This study provides the first direct evidence from intracellular recordings that phase 2 EAD could be generated from rabbit intact hypertrophied LV wall in the absence of APD prolonging agents, resulting in R on T extrasystoles capable of initiating polymorphic VT under enhanced TDR.


Assuntos
Potenciais de Ação/fisiologia , Hipertrofia Ventricular Esquerda/fisiopatologia , Taquicardia Ventricular/fisiopatologia , Complexos Ventriculares Prematuros/fisiopatologia , Animais , Endocárdio/fisiopatologia , Coelhos
5.
Circulation ; 103(23): 2851-6, 2001 Jun 12.
Artigo em Inglês | MEDLINE | ID: mdl-11401944

RESUMO

BACKGROUND: This study examined the role of phase 2 early afterdepolarization (EAD) in producing a trigger to initiate torsade de pointes (TdP) with QT prolongation induced by dl-sotalol and azimilide. The contribution of transmural dispersion of repolarization (TDR) to transmural propagation of EAD and the maintenance of TdP was also evaluated. METHODS AND RESULTS: Transmembrane action potentials from epicardium, midmyocardium, and endocardium were recorded simultaneously, together with a transmural ECG, in arterially perfused canine and rabbit left ventricular preparations. dl-Sotalol preferentially prolonged action potential duration (APD) in M cells dose-dependently (1 to 100 micromol/L), leading to QT prolongation and an increase in TDR. Azimilide, however, significantly prolonged APD and QT interval at concentrations from 0.1 to 10 micromol/L but shortened them at 30 micromol/L. Unlike dl-sotalol, azimilide (>3 micromol/L) increased epicardial APD markedly, causing a diminished TDR. Although both dl-sotalol and azimilide rarely induced EADs in canine left ventricles, they produced frequent EADs in rabbits, in which more pronounced QT prolongation was seen. An increase in TDR by dl-sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles. Of note, although azimilide (3 to 10 micromol/L) increased APD more than dl-sotalol, its EADs often failed to propagate transmurally, probably because of a diminished TDR. CONCLUSIONS: This study provides the first direct evidence from intracellular action potential recordings that phase 2 EAD can be generated from intact ventricular wall and produce a trigger to initiate the onset of TdP under QT prolongation.


Assuntos
Sistema de Condução Cardíaco/fisiopatologia , Imidazolidinas , Síndrome do QT Longo/fisiopatologia , Taquicardia Ventricular/fisiopatologia , Disfunção Ventricular Esquerda/fisiopatologia , Potenciais de Ação/efeitos dos fármacos , Animais , Antiarrítmicos/farmacologia , Cães , Relação Dose-Resposta a Droga , Eletrocardiografia/efeitos dos fármacos , Técnicas Eletrofisiológicas Cardíacas , Sistema de Condução Cardíaco/efeitos dos fármacos , Ventrículos do Coração/efeitos dos fármacos , Ventrículos do Coração/fisiopatologia , Hidantoínas , Imidazóis/farmacologia , Técnicas In Vitro , Síndrome do QT Longo/complicações , Contração Miocárdica/efeitos dos fármacos , Piperazinas/farmacologia , Coelhos , Sotalol/farmacologia , Especificidade da Espécie , Sístole/efeitos dos fármacos , Taquicardia Ventricular/complicações , Disfunção Ventricular Esquerda/etiologia
6.
Pacing Clin Electrophysiol ; 24(2): 191-3, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11270698

RESUMO

This was a retrospective analysis of patients who had CABG surgery at our hospital over a 12-month period to determine the intermediate-term prognosis of those who had developed PAF after their operation before hospital discharge. Of 317 patients who were operated by a single surgical group, 116 (37%) had AF postoperatively of whom 112 had the paroxysmal form. Of these, 36 were treated with class I or III antiarrhythmic drugs and rate control drugs (group 1) and 76 were treated with rate control alone (group 2). Group 3 consisted of 151 randomly selected patients who did not have AF. All patients were reevaluated at 6 weeks to determine their rhythm and clinical status. Only one patient each in groups 1 and 2 was in AF 6 weeks after discharge. There was a trend toward a higher mortality and morbidity in group 2 patients. PAF after coronary surgery appears to be a self-limited disease process. In this cohort of patients, the rate of recurrence of AF after discharge was similar in patients receiving class I or class III antiarrhythmic drugs together with rate control agents compared to those receiving rate control drugs alone.


Assuntos
Fibrilação Atrial/epidemiologia , Ponte de Artéria Coronária , Complicações Pós-Operatórias/epidemiologia , Antagonistas Adrenérgicos beta/uso terapêutico , Idoso , Antiarrítmicos/uso terapêutico , Fibrilação Atrial/tratamento farmacológico , Bloqueadores dos Canais de Cálcio/uso terapêutico , Estudos de Casos e Controles , Digoxina/uso terapêutico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Morbidade , Complicações Pós-Operatórias/tratamento farmacológico , Prognóstico , Distribuição Aleatória , Recidiva , Estudos Retrospectivos , Fatores de Tempo
7.
Circulation ; 103(11): 1585-90, 2001 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-11257089

RESUMO

BACKGROUND: Delayed rectifier K(+) currents are critical to action potential (AP) repolarization. The present study examines the effects of left ventricular hypertrophy (LVH) on delayed rectifier K(+) currents and their contribution to AP repolarization in both epicardial (Epi) and endocardial (Endo) myocytes. METHODS AND RESULTS: VH was induced in rabbits by a 1-kidney removal, 1-kidney vascular clamping method. Slowly (I(Ks)) and rapidly (I(Kr)) activating delayed rectifier K(+) currents were recorded by the whole-cell patch-clamp technique, and APs were recorded by the microelectrode technique. In normal rabbit left ventricular myocytes, I(Ks) densities were larger in Epi than in Endo (1.1+/-0.1 versus 0.43+/-0.07 pA/pF), whereas I(Kr) density was similar between Epi and Endo (0.31+/-0.05 versus 0.36+/-0.07 pA/pF) at 20 mV. LVH reduced I(Ks) density to a similar extent (approximately 40%) in both Epi and Endo but had no significant effect on I(Kr) in either Epi or Endo. Consequently, I(Kr) was expected to contribute more to AP repolarization in LVH than in control. This was confirmed by specific I(Kr) block with dofetilide, which prolonged AP significantly more in LVH than in control (31+/-3% versus 18+/-2% in Epi; 53+/-6% versus 32+/-4% in Endo at 2 Hz). In contrast, L-768,673 (a specific I(Ks) blocker) prolonged AP less in LVH than in control. The very small I(Ks) density in Endo with LVH is consistent with the greater incidence of early afterdepolarizations induced in this region by dofetilide. CONCLUSIONS: LVH induces a decrease in I(Ks) density and increases the propensity to develop early afterdepolarizations, especially in Endo.


Assuntos
Potenciais de Ação/fisiologia , Endocárdio/fisiopatologia , Hipertrofia Ventricular Esquerda/fisiopatologia , Pericárdio/fisiopatologia , Canais de Potássio de Abertura Dependente da Tensão da Membrana , Canais de Potássio/metabolismo , Animais , Canais de Potássio de Retificação Tardia , Eletrofisiologia , Masculino , Miocárdio/metabolismo , Coelhos
8.
J Cardiovasc Pharmacol ; 37(3): 317-23, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11243422

RESUMO

Left ventricular hypertrophy (LVH) is associated with abnormal ventricular electrophysiology. We have shown complete regression of LVH and normalization of ventricular electrophysiology in renovascular hypertensive rabbits treated with captopril. To determine if angiotensin II type 1 receptor (AT1) blockade produces the same benefit, we treated hypertensive rabbits with losartan for 3 months. LVH was evaluated by heart-to-body weight ratio (HW/BW). Vulnerability to ventricular arrhythmia was assessed by ventricular fibrillation threshold (VFT) and dispersion of effective refractory period (ERP). The electrical properties of single left ventricular myocytes were characterized by action potential duration at 90% repolarization (APD90) and inward rectifier K+ current (I(K1)) density. Hypertensive rabbits treated with vehicle (LVH/Vehicle) had higher mean arterial pressure (MAP, 81+/-2 vs. 60+/-2 mm Hg) and HW/BW (2.71+/-0.07 vs. 1.97+/-0.04 g/kg), lower VFT (20+/-1 vs. 39+/-2 mA), larger dispersion of ERP (34+/-3 vs. 14+/-3 ms), longer APD90 (187+/-6 vs. 162+/-6 ms) and lower I(K1) density compared with control rabbits. Hypertensive rabbits treated with losartan (LVH/Losartan) had HW/BW (2.36+/-0.06 g/kg) between those of LVH/Vehicle and control rabbits, whereas MAP (65+/-2 mm Hg), VFT (34+/-2 mA), dispersion of ERP (19+/-1 ms), APD90 (160+/-6 ms), and I(K1) density were significantly different from LVH/Vehicle but similar to control. We conclude that AT1 blockade in renovascular hypertensive rabbits normalizes ventricular electrophysiology.


Assuntos
Anti-Hipertensivos/uso terapêutico , Hipertensão Renovascular/tratamento farmacológico , Losartan/uso terapêutico , Potenciais de Ação/efeitos dos fármacos , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Animais , Hipertensão Renovascular/fisiopatologia , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Masculino , Coelhos , Período Refratário Eletrofisiológico/efeitos dos fármacos
9.
Am J Cardiol ; 87(4): 432-5, 2001 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-11179527

RESUMO

The tablet form of amiodarone is indicated for the treatment of recurrent ventricular fibrillation or hemodynamically unstable ventricular tachycardia. It is recommended that the tablet be taken with meals in cases of gastrointestinal intolerance. However, the effect of food on its bioavailability is unknown. The primary objective of this study was to determine the effect of food on the bioavailability of amiodarone. This was a 2-period crossover study conducted in 30 healthy male subjects. Subjects were randomly assigned to 1 of 2 sequences in which the following 2 treatments were administered: (1) a single-dose of amiodarone (three 200-mg Cordarone tablets) after an overnight fast, and (2) the same dose immediately after a standard high-fat breakfast. Plasma concentrations of amiodarone and desethylamiodarone (DEA) were measured for 6 weeks after each dose. Food enhanced the extent of absorption, resulting in a peak concentration (Cmax) and area under the curve (AUCT) 3.8 and 2.4 times the respective values under fasting conditions. Food also significantly increased the rate of absorption, reducing the time (tmax) to Cmax from 7.1 to 4.5 hours. The effect of food on DEA levels was significant but less pronounced. An in vitro dissolution study confirmed a marked difference between amiodarone release under simulated fed and fasting conditions. Thus, food significantly enhances both the rate and extent of absorption of amiodarone, which is attributed partially to the effect of food on drug release from its formulation. Therefore, it is recommended that amiodarone tablets be taken consistently with meals.


Assuntos
Amiodarona/farmacocinética , Antiarrítmicos/farmacocinética , Alimentos , Adulto , Amiodarona/administração & dosagem , Análise de Variância , Antiarrítmicos/administração & dosagem , Área Sob a Curva , Disponibilidade Biológica , Cromatografia Líquida de Alta Pressão , Humanos , Masculino , Comprimidos
10.
Arch Intern Med ; 160(16): 2429-36, 2000 Sep 11.
Artigo em Inglês | MEDLINE | ID: mdl-10979053

RESUMO

This article is the result of a meeting of the National Council on Potassium in Clinical Practice. The Council, a multidisciplinary group comprising specialists in cardiology, hypertension, epidemiology, pharmacy, and compliance, was formed to examine the critical role of potassium in clinical practice. The goal of the Council was to assess the role of potassium in terms of current medical practice and future clinical applications. The primary outcome of the meeting was the development of guidelines for potassium replacement therapy. These guidelines represent a consensus of the Council members and are intended to provide a general approach to the prevention and treatment of hypokalemia.


Assuntos
Hipopotassemia/terapia , Potássio na Dieta/uso terapêutico , Arritmias Cardíacas/fisiopatologia , Insuficiência Cardíaca/fisiopatologia , Humanos , Hipertensão/fisiopatologia , Hipopotassemia/fisiopatologia , Magnésio/fisiologia , Potássio na Dieta/administração & dosagem
12.
Am Heart J ; 140(1): 12-20, 2000 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-10874257

RESUMO

Despite the emergence of several forms of nonpharmacologic therapy for cardiac arrhythmias, antiarrhythmic drugs continue to play an important role in the management of patients with this common clinical problem. The key to the proper use of antiarrhythmic drugs is a thorough knowledge of their mode of action and pharmacology. The pharmacology of antiarrhythmic drugs is particularly important because patients with cardiac arrhythmias frequently have multiorgan disease, which may influence the metabolism and elimination of antiarrhythmic drugs. The accumulation of toxic amounts of these agents can lead to dire effects including, but not limited to, ventricular proarrhythmia and malignant bradycardia. The goals of pharmacologic therapy of cardiac arrhythmia are to provide the maximum benefit in terms of arrhythmia suppression while maintaining patient safety. To accomplish these goals, a knowledge of the pharmacology of several antiarrhythmic drugs is mandatory.


Assuntos
Antiarrítmicos/classificação , Antiarrítmicos/farmacologia , Idoso , Antiarrítmicos/administração & dosagem , Arritmias Cardíacas/tratamento farmacológico , Relação Dose-Resposta a Droga , Interações Medicamentosas , Humanos , Sensibilidade e Especificidade
13.
Am J Cardiol ; 85(10A): 20D-24D, 2000 May 25.
Artigo em Inglês | MEDLINE | ID: mdl-10822037

RESUMO

Atrial arrhythmias occur frequently after cardiac surgery. This article discusses the incidence of postoperative atrial arrhythmia as well as its prognosis, potential mechanisms of pathogenesis, and management. Prophylactic therapy for postoperative atrial arrhythmia is recommended because of the frequency of occurrence and the ease with which therapies can often be implemented. Treatments with pharmacologic and nonpharmacologic modalities are described. Management strategies for atrial arrhythmias that occur postoperatively, including pharmacologic and nonpharmacologic measures as well as anticoagulation recommendations, are discussed.


Assuntos
Fibrilação Atrial/terapia , Procedimentos Cirúrgicos Cardíacos , Complicações Pós-Operatórias , Antagonistas Adrenérgicos beta/uso terapêutico , Antiarrítmicos/uso terapêutico , Fibrilação Atrial/etiologia , Fibrilação Atrial/prevenção & controle , Estimulação Cardíaca Artificial , Humanos , Prognóstico , Fatores de Risco , Sotalol/uso terapêutico
14.
Clin Cardiol ; 23(3): 171-4, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10761804

RESUMO

BACKGROUND: Patients with inducible sustained ventricular tachycardia (VT) sometimes receive intravenous procainamide during electrophysiologic testing. Unfortunately, the responses to intravenous and subsequent oral drug therapy are variable and may be discordant. HYPOTHESIS: It was the aim of this study to determine whether this variability might be explained by heterogeneity in the electropharmacologic response, even in a homogeneous population. METHODS: We studied 42 patients who had spontaneous malignant ventricular arrhythmia and were inducible to sustained monomorphous VT during electrophysiologic testing. Each received 15 mg/kg of intravenous procainamide followed by a 2 mg/min infusion. Serum levels were drawn immediately following programmed stimulation. The mean procainamide level was 6.7 +/- 1.4 mcg/ml with an N-acetyl procainamide level of 1.0 +/- 0.5 mcg/ml. The 14 procainamide responders (5 of whom were noninducible and 9 whose VT cycle length increased > 100 ms) and the 28 nonresponders had similar procainamide and NAPA levels (6.5 +/- 1.4 vs. 6.7 +/- 1.4 mcg/ml). RESULTS: There was no significant difference in baseline clinical parameters, His to ventricular electrogram (HV) interval, effective refractory period, or VT cycle length. Prolongation of the effective refractory period and infra His conduction time occurred to a similar extent in responders and nonresponders. CONCLUSION: We conclude that procainamide has a consistent dose-response relationship with respect to refractoriness and conduction in patients with malignant arrhythmias. However, acute antiarrhythmic efficacy of procainamide cannot be predicted by clinical factors, drug levels, or drug-induced changes in common electrophysiologic parameters.


Assuntos
Antiarrítmicos/farmacologia , Sistema de Condução Cardíaco/efeitos dos fármacos , Procainamida/farmacologia , Taquicardia Ventricular/tratamento farmacológico , Idoso , Antiarrítmicos/administração & dosagem , Antiarrítmicos/sangue , Antiarrítmicos/uso terapêutico , Fascículo Atrioventricular/efeitos dos fármacos , Relação Dose-Resposta a Droga , Eletrofisiologia , Feminino , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Procainamida/administração & dosagem , Procainamida/sangue , Procainamida/uso terapêutico
15.
Am J Cardiol ; 85(9): 1151-3, A10, 2000 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-10781771

RESUMO

The consequences of antiarrhythmic drug formulation substitution were assessed by survey of 130 experts on arrhythmias. Fifty-four arrhythmia recurrences, 7 proarrhythmic events, and 3 deaths resulting from generic substitution are reported, thus raising serious concerns about both antiarrhythmic drug substitution and the adequacy of the generic drug approval process.


Assuntos
Antiarrítmicos/farmacocinética , Taquicardia/tratamento farmacológico , Amiodarona/farmacocinética , Amiodarona/uso terapêutico , Antiarrítmicos/uso terapêutico , Pesquisas sobre Atenção à Saúde , Humanos , Equivalência Terapêutica
16.
Am Heart J ; 139(4): 690-5, 2000 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10740153

RESUMO

BACKGROUND: Intravenous amiodarone is effective for the acute suppression of recurrent hemodynamically destabilizing ventricular arrhythmias. There are no follow-up data on patients undergoing long-term therapy with intravenous amiodarone. The objective of this investigation was to evaluate long-term outcome. METHODS AND RESULTS: We reviewed the clinical courses of 245 patients given intravenous amiodarone for sustained ventricular tachyarrhythmias. Of the 107 survivors (84% men; mean age 64 years) released from the hospital taking oral amiodarone, 41 were discharged with an empiric prescription for oral amiodarone. For 64 patients a decision regarding further therapy was based on results of an electrophysiologic study. Two patients were treated empirically with oral amiodarone and an implantable cardioverter defibrillator. Clinical variables and survival curves were the same for the empirically treated group and the group whose treatment was based on electrophysiologic findings (P =.89). Survival at 6, 12, and 18 months was 88%, 81% and 71%, respectively, for empirically treated patients, and 83%, 80% and 73%, respectively, for patients whose therapy was directed with an electrophysiologic study. Of the 64 patients who underwent electrophysiologic studies, 33 received an implantable cardioverter defibrillator. The Kaplan-Meier survival curves for patients with and patients without an implantable cardioverter defibrillator were similar (P =.46). CONCLUSIONS: Patients for whom recurrent ventricular tachycardia and fibrillation are suppressed with intravenous amiodarone and who are discharged receiving oral amiodarone have an 80% 1-year survival rate. Although not randomized, our data suggested that among such patients, electrophysiologic testing, implantation of a cardioverter defibrillator, or both may not be necessary. Ascertaining the best management strategy for these patients will require a prospective randomized trial.


Assuntos
Amiodarona/administração & dosagem , Antiarrítmicos/administração & dosagem , Hemodinâmica/efeitos dos fármacos , Taquicardia Ventricular/tratamento farmacológico , Idoso , Amiodarona/efeitos adversos , Antiarrítmicos/efeitos adversos , Ensaios Clínicos como Assunto , Terapia Combinada , Desfibriladores Implantáveis , Eletrocardiografia/efeitos dos fármacos , Feminino , Seguimentos , Hemodinâmica/fisiologia , Mortalidade Hospitalar , Humanos , Infusões Intravenosas , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Recidiva , Taxa de Sobrevida , Taquicardia Ventricular/mortalidade , Taquicardia Ventricular/fisiopatologia
18.
J Pharmacol Exp Ther ; 292(1): 196-200, 2000 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-10604948

RESUMO

beta-Adrenergic stimulation of cardiac L-type Ca(2+) channels is severely impaired in hypertrophied and failing hearts of both experimental animals and humans. The aim of this study was to test the hypothesis that chronic treatment of renovascular hypertension with captopril restores normal beta-adrenergic responsiveness of L-type Ca(2+) channels in cardiac myocytes. Left ventricular hypertrophy was induced in rabbits by unilateral renal artery banding and contralateral nephrectomy. Beginning at 3 months after banding, hypertensive rabbits were treated with captopril for 3 months. The responsiveness of L-type Ca(2+) current (I(Ca,L)) to (+/-)-isoproterenol was investigated with the whole-cell patch-clamp technique. (+/-)-Isoproterenol (1 microM) induced an increase of I(Ca,L) at 0 mV of 126 +/- 20% (n = 13) in control myocytes versus 69 +/- 11% (n = 18) in hypertrophied myocytes from rabbits 3 months after banding. The half-maximal activation concentration of (+/-)-isoproterenol was similar between control and hypertrophied myocytes. Forskolin (10 microM) induced a similar percentage of increase of I(Ca,L) in control and hypertrophied myocytes, 109 +/- 13% (n = 12) versus 120 +/- 14% (n = 11) at 0 mV. The responsiveness of I(Ca,L) to (+/-)-isoproterenol remained depressed in untreated hypertensive rabbits. (+/-)-Isoproterenol (1 microM) increased I(Ca, L) at 0 mV by 64 +/- 8% (n = 14) in myocytes isolated from rabbits 6 months after banding versus 111 +/- 15% (n = 16) in age-matched controls. In captopril-treated rabbits, 1 microM (+/-)-isoproterenol increased I(Ca,L) by 110 +/- 11% (n = 17). We conclude that the maximal response of I(Ca,L) to (+/-)-isoproterenol was severely depressed in hypertrophied myocytes. Chronic treatment of renovascular hypertension with captopril can restore normal responsiveness of I(Ca,L) to (+/-)-isoproterenol in cardiac myocytes.


Assuntos
Canais de Cálcio/efeitos dos fármacos , Captopril/farmacologia , Coração/efeitos dos fármacos , Hipertensão Renovascular/tratamento farmacológico , Receptores Adrenérgicos beta/efeitos dos fármacos , Animais , Captopril/uso terapêutico , Colforsina/farmacologia , Relação Dose-Resposta a Droga , Interações Medicamentosas , Hipertensão Renovascular/fisiopatologia , Hipertrofia Ventricular Esquerda/tratamento farmacológico , Hipertrofia Ventricular Esquerda/fisiopatologia , Isoproterenol/farmacologia , Nefrectomia , Técnicas de Patch-Clamp , Coelhos , Distribuição Aleatória , Receptores Adrenérgicos beta/fisiologia , Artéria Renal/cirurgia , Fatores de Tempo
19.
Am J Cardiol ; 84(9A): 46R-51R, 1999 Nov 04.
Artigo em Inglês | MEDLINE | ID: mdl-10568659

RESUMO

Ventricular tachycardia, which causes hemodynamic instability, and ventricular fibrillation do not occur frequently in any hospital. However, they usually occur in patients who have severe underlying cardiovascular disease such as myocardial ischemia/infarction or congestive heart failure, and they are associated with high mortality. Most of those deaths are due to an intractable arrhythmia, not suppressible with even the most potent antiarrhythmic drugs. Fortunately, during the last few years, our ability to suppress highly lethal ventricular arrhythmia has been enhanced by the approval of intravenous amiodarone. When used in appropriate patient populations, intravenous amiodarone has been successful in suppressing the most malignant arrhythmia, thus permitting aggressive and successful treatment of severe underlying cardiac conditions. This article reviews data on the use of parenteral antiarrhythmic drugs for the control of ventricular arrhythmia in patients in hospital, and will attempt to provide some guidance as to how these antiarrhythmic drugs may be used in specific patient populations to maximize their efficacy and safety. We will also make recommendations on the sequence of therapy for specific arrhythmias to optimize the chances of patient survival.


Assuntos
Amiodarona/administração & dosagem , Antiarrítmicos/administração & dosagem , Hospitalização , Taquicardia Ventricular/tratamento farmacológico , Fibrilação Ventricular/tratamento farmacológico , Amiodarona/efeitos adversos , Amiodarona/farmacocinética , Antiarrítmicos/efeitos adversos , Antiarrítmicos/farmacocinética , Relação Dose-Resposta a Droga , Esquema de Medicação , Hemodinâmica/efeitos dos fármacos , Humanos , Infusões Intravenosas , Taquicardia Ventricular/sangue , Taquicardia Ventricular/etiologia , Fibrilação Ventricular/sangue , Fibrilação Ventricular/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA